KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) EBIAT (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EBIAT for 16 consecutive years, with $111.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT rose 233.17% year-over-year to $111.5 million, compared with a TTM value of $319.7 million through Dec 2025, up 214.93%, and an annual FY2025 reading of $313.7 million, up 212.79% over the prior year.
  • EBIAT was $111.5 million for Q4 2025 at Alnylam Pharmaceuticals, down from $292.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $292.7 million in Q3 2025 and bottomed at -$405.9 million in Q3 2022.
  • Average EBIAT over 5 years is -$119.1 million, with a median of -$156.0 million recorded in 2023.
  • Peak annual rise in EBIAT hit 362.33% in 2025, while the deepest fall reached 292.43% in 2025.
  • Year by year, EBIAT stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then soared by 233.17% to $111.5 million in 2025.
  • Business Quant data shows EBIAT for ALNY at $111.5 million in Q4 2025, $292.7 million in Q3 2025, and -$66.3 million in Q2 2025.